Avion Wealth’s Day One Biopharmaceuticals DAWN Stock Holding History

Avion Wealth’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-37	Closed	–	–	1122
2023 Q3	$0	Buy	+37	New	+$483	﹤0.01%	873

Other funds holding DAWN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Avion Wealth's DAWN Position: Q4 2023 in Review

Avion Wealth sold out of Day One Biopharmaceuticals (DAWN) in Q4 2023, closing a stake of 37 shares.

Avion Wealth first reported a position in DAWN in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 139 funds tracked by Wall St. Rank hold DAWN as of Q4 2023.

Avion Wealth reported no remaining Day One Biopharmaceuticals position as of Q4 2023 after selling out during the quarter.
Avion Wealth sold 37 Day One Biopharmaceuticals shares in Q4 2023.
Avion Wealth first reported a position in Day One Biopharmaceuticals in Q3 2023 and held it in 1 quarter.
Avion Wealth's Day One Biopharmaceuticals position peaked at $0 in Q3 2023.
139 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2023.

Based on Avion Wealth's 13F filing for Q4 2023, filed 26 Jan 2024.